Hong Kong Stock Alert | TRANSCENTA-B Surges Over 11% Pre-Noon, Plans to Sell CDMO Assets for 190 Million Yuan

Stock News11:32

TRANSCENTA-B (06628) saw its shares jump more than 11% before the noon trading session on Tuesday. As of press time, the stock was up 11.22% at HK$1.14, with a trading volume of HK$340,700.

On the news front, TRANSCENTA-B announced that on August 6, 2026, after the trading session, the seller (a wholly-owned subsidiary of the company) and the buyer, Hangzhou Mingde Biomedical Technology Co., Ltd., entered into an asset purchase agreement. Under the terms, the seller conditionally agreed to sell, and the buyer conditionally agreed to purchase, the CDMO assets for a total consideration of RMB 190 million (subject to adjustments as detailed in the asset purchase agreement).

Upon completion of the second phase, the company will no longer hold any interest in the CDMO assets. The CDMO assets primarily include the GMP manufacturing facilities historically used by the group to provide CDMO services. The transaction does not involve the sale of any intellectual property held by the group related to its drug candidate pipeline or its core biomanufacturing platforms and technologies, including the highly intensified continuous bioprocessing (HiCB) platform and the cell culture medium ExcelPro CHO.

Following the completion of the transaction, the company will continue to generate revenue through out-licensing and collaboration arrangements related to these core CDMO service technologies.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1120126108?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-07 11:32","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1120126108","market":"nz","top_or_hot":-1,"title":"Hong Kong Stock Alert | TRANSCENTA-B Surges Over 11% Pre-Noon, Plans to Sell CDMO Assets for 190 Million Yuan","media":"Stock News","content":"<p><b>TRANSCENTA-B</b> (06628) saw its shares jump more than 11% before the noon trading session on Tuesday. As of press time, the stock was up 11.22% at HK$1.14, with a trading volume of HK$340,700.<br><br>On the news front, <b>TRANSCENTA-B</b> announced that on August 6, 2026, after the trading session, the seller (a wholly-owned subsidiary of the company) and the buyer, Hangzhou Mingde Biomedical Technology Co., Ltd., entered into an asset purchase agreement. Under the terms, the seller conditionally agreed to sell, and the buyer conditionally agreed to purchase, the CDMO assets for a total consideration of RMB 190 million (subject to adjustments as detailed in the asset purchase agreement).<br><br>Upon completion of the second phase, the company will no longer hold any interest in the CDMO assets. The CDMO assets primarily include the GMP manufacturing facilities historically used by the group to provide CDMO services. The transaction does not involve the sale of any intellectual property held by the group related to its drug candidate pipeline or its core biomanufacturing platforms and technologies, including the highly intensified continuous bioprocessing (HiCB) platform and the cell culture medium ExcelPro CHO.<br><br>Following the completion of the transaction, the company will continue to generate revenue through out-licensing and collaboration arrangements related to these core CDMO service technologies.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Hong Kong Stock Alert | TRANSCENTA-B Surges Over 11% Pre-Noon, Plans to Sell CDMO Assets for 190 Million Yuan</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHong Kong Stock Alert | TRANSCENTA-B Surges Over 11% Pre-Noon, Plans to Sell CDMO Assets for 190 Million Yuan\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-08-07 11:32</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><b>TRANSCENTA-B</b> (06628) saw its shares jump more than 11% before the noon trading session on Tuesday. As of press time, the stock was up 11.22% at HK$1.14, with a trading volume of HK$340,700.<br><br>On the news front, <b>TRANSCENTA-B</b> announced that on August 6, 2026, after the trading session, the seller (a wholly-owned subsidiary of the company) and the buyer, Hangzhou Mingde Biomedical Technology Co., Ltd., entered into an asset purchase agreement. Under the terms, the seller conditionally agreed to sell, and the buyer conditionally agreed to purchase, the CDMO assets for a total consideration of RMB 190 million (subject to adjustments as detailed in the asset purchase agreement).<br><br>Upon completion of the second phase, the company will no longer hold any interest in the CDMO assets. The CDMO assets primarily include the GMP manufacturing facilities historically used by the group to provide CDMO services. The transaction does not involve the sale of any intellectual property held by the group related to its drug candidate pipeline or its core biomanufacturing platforms and technologies, including the highly intensified continuous bioprocessing (HiCB) platform and the cell culture medium ExcelPro CHO.<br><br>Following the completion of the transaction, the company will continue to generate revenue through out-licensing and collaboration arrangements related to these core CDMO service technologies.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1161","symbol_name":"生物科技","start_time":0,"source_url":"","article_id":"1120126108","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1120126108","pubTimestamp":1786073536,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"TRANSCENTA-B (06628) saw its shares jump more than 11% before the noon trading session on Tuesday. As of press time, the stock was up 11.22% at HK$1.14, with a trading volume of HK$340,700.On the...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"159938":"医药","BK1161":"生物科技","BK1515":"抗疫概念","BK1574":"生物医药B类股","KCAI":"KraneShares China Alpha Index ETF","BK4139":"生物科技","BK4585":"ETF&股票定投概念","06628":"创胜集团医药-B","09939":"开拓药业-B","BK4588":"碎股","CDMO":"Avid Bioservices, Inc.","VXUS":"国际股票ETF-Vanguard"},"translate_title":"港股预警|TRANSCENTA-B午前大涨逾11% 拟1.9亿元出售CDMO资产","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"159938":1,"CDMO":1,"KCAI":1,"VXUS":1,"09939":1,"06628":1},"content_text":"TRANSCENTA-B (06628) saw its shares jump more than 11% before the noon trading session on Tuesday. As of press time, the stock was up 11.22% at HK$1.14, with a trading volume of HK$340,700.On the news front, TRANSCENTA-B announced that on August 6, 2026, after the trading session, the seller (a wholly-owned subsidiary of the company) and the buyer, Hangzhou Mingde Biomedical Technology Co., Ltd., entered into an asset purchase agreement. Under the terms, the seller conditionally agreed to sell, and the buyer conditionally agreed to purchase, the CDMO assets for a total consideration of RMB 190 million (subject to adjustments as detailed in the asset purchase agreement).Upon completion of the second phase, the company will no longer hold any interest in the CDMO assets. The CDMO assets primarily include the GMP manufacturing facilities historically used by the group to provide CDMO services. The transaction does not involve the sale of any intellectual property held by the group related to its drug candidate pipeline or its core biomanufacturing platforms and technologies, including the highly intensified continuous bioprocessing (HiCB) platform and the cell culture medium ExcelPro CHO.Following the completion of the transaction, the company will continue to generate revenue through out-licensing and collaboration arrangements related to these core CDMO service technologies.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"0","news_tag":"shareholding","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1120126108","isCrawlerRequest":true}